{"id":"NCT02569541","sponsor":"Arrevus Inc.","briefTitle":"Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections","officialTitle":"An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-12","primaryCompletion":"2017-10-17","completion":"2019-02-21","firstPosted":"2015-10-06","resultsPosted":"2020-01-30","lastUpdate":"2020-01-30"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Refractory Bone or Joint Infections"],"interventions":[{"type":"DRUG","name":"sodium fusidate","otherNames":["CEM-102","fusidic acid"]}],"arms":[{"label":"CEM-102 (Sodium fusidate)","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and effectiveness of oral sodium fusidate (CEM-102) as chronic antibiotic for the treatment of bone or joint infections.","primaryOutcome":{"measure":"Clinical Success at 6 Months","timeFrame":"6 months after start of treatment","effectByArm":[{"arm":"CEM-102 (Sodium Fusidate)","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":30},"commonTop":["Urinary tract infection","Anaemia","Nausea","Oedema peripheral","Peripheral swelling"]}}